FDA approves Koselugo to treat paediatric patients two years of age and older with neurofibromatosis type 1 (NF1). – AstraZeneca + Merck Inc.
AstraZeneca and Merck Inc.announced that the FDA has approved the kinase inhibitor Koselugo (selumetinib) for the treatment of paediatric patients two years of age and older with neurofibromatosis… read more.